FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3213679265> ?p ?o ?g. }

• W3213679265 endingPage "2966" @default.
• W3213679265 startingPage "2966" @default.
• W3213679265 abstract "Abstract Background: Direct oral anticoagulants (DOACs) are rapidly replacing alternative agents as the preferred choice for anticoagulation. With extended time on the market and expanded guidelines for indications for use, they are now more accessible and affordable. Qualifying patients previously treated with warfarin for long-term anticoagulation may benefit from transitioning to a DOAC. In this prospective quality improvement study, we seek to identify eligible patients and transition them from warfarin to DOAC via shared decision-making and a multidisciplinary approach. Additionally, we will assess changes in quality of life (QOL) through a validated survey. Methods: Identify patients currently on warfarin who are eligible for transition to a DOAC. Eligibility criteria include patients with age &gt;18 years old. Exclusion criteria includes pregnancy, BMI &gt;50 kg/m2, CrCl &lt;15 L/min, patients receiving anticoagulation for APLS or for mechanical heart valves. With the aid of our pharmacy team, we then ensure long-term medication affordability prior to transition. Eligible patients complete a QOL survey pre-transition and 3 months post-transition. The QOL survey is the validated Anti-Clot Treatment Scale (ACTS), which is a 15 question survey which includes a Burden scale composed of 12 questions and a Benefit scale composed of 3 questions and each question is scored from 1 to 5 (1=not at all, 2=a little, 3=moderately, 4=quite a bit, 5=extremely). The Burden scale is reverse scored so that higher ACTS Burden scores indicate greater satisfaction for a score range of 12-60. The Benefit scale is scored conventionally for a score range of 3-15. The Total score is calculated by the addition of the Burden scale and Benefit scale for a score range of 15-75. Paired T-tests were conducted on the Burden scale, Benefit scale, and Total score using GraphPad Prism version 7 (GraphPad Software, La Jolla, CA). P-values were two-tailed, with a p&lt;0.05 considered statistically significant. Results: 25 patients out of 60 were identified as eligible for DOAC transition. Total score, Burden scale, and Benefit scale mean values were 49.5, 39.5, 10 for warfarin and 66.8, 53.5, and 13.3 for DOAC, respectively. Preliminary conducted analysis revealed statistically significant improvements in Total, Burden, and Benefit scores with p-values of 0.0046, 0.0075, and 0.0319 and mean improvements of 17.3, 14, and 3.25, respectively. Conclusion: Transitioning patients from warfarin to a DOAC has been found to decrease both patients' sense of burden while also improving their sense of benefit, as evidenced by the QOL survey analysis. Transitioning patients from warfarin to a DOAC has the potential to decrease need for routine INR monitoring, dietary limitations, and fewer drug interactions. Additionally, it improves patient satisfaction with their healthcare and reduces utilization of healthcare resources. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare." @default.
• W3213679265 created "2021-11-22" @default.
• W3213679265 creator A5001269856 @default.
• W3213679265 creator A5010902953 @default.
• W3213679265 creator A5018837836 @default.
• W3213679265 creator A5026333806 @default.
• W3213679265 creator A5038701347 @default.
• W3213679265 creator A5059403790 @default.
• W3213679265 creator A5065124429 @default.
• W3213679265 creator A5077357766 @default.
• W3213679265 date "2021-11-05" @default.
• W3213679265 modified "2023-10-01" @default.
• W3213679265 title "Transitioning Eligible Patients from Warfarin to a Direct Oral Anticoagulant: A Prospective Quality Improvement Study" @default.
• W3213679265 doi "https://doi.org/10.1182/blood-2021-151830" @default.
• W3213679265 hasPublicationYear "2021" @default.
• W3213679265 type Work @default.
• W3213679265 sameAs 3213679265 @default.
• W3213679265 citedByCount "1" @default.
• W3213679265 countsByYear W32136792652022 @default.
• W3213679265 crossrefType "journal-article" @default.
• W3213679265 hasAuthorship W3213679265A5001269856 @default.
• W3213679265 hasAuthorship W3213679265A5010902953 @default.
• W3213679265 hasAuthorship W3213679265A5018837836 @default.
• W3213679265 hasAuthorship W3213679265A5026333806 @default.
• W3213679265 hasAuthorship W3213679265A5038701347 @default.
• W3213679265 hasAuthorship W3213679265A5059403790 @default.
• W3213679265 hasAuthorship W3213679265A5065124429 @default.
• W3213679265 hasAuthorship W3213679265A5077357766 @default.
• W3213679265 hasBestOaLocation W32136792651 @default.
• W3213679265 hasConcept C104863432 @default.
• W3213679265 hasConcept C126322002 @default.
• W3213679265 hasConcept C144024400 @default.
• W3213679265 hasConcept C159110408 @default.
• W3213679265 hasConcept C177713679 @default.
• W3213679265 hasConcept C1862650 @default.
• W3213679265 hasConcept C188816634 @default.
• W3213679265 hasConcept C22467394 @default.
• W3213679265 hasConcept C2776301958 @default.
• W3213679265 hasConcept C2779161974 @default.
• W3213679265 hasConcept C2779951463 @default.
• W3213679265 hasConcept C36289849 @default.
• W3213679265 hasConcept C512399662 @default.
• W3213679265 hasConcept C71924100 @default.
• W3213679265 hasConceptScore W3213679265C104863432 @default.
• W3213679265 hasConceptScore W3213679265C126322002 @default.
• W3213679265 hasConceptScore W3213679265C144024400 @default.
• W3213679265 hasConceptScore W3213679265C159110408 @default.
• W3213679265 hasConceptScore W3213679265C177713679 @default.
• W3213679265 hasConceptScore W3213679265C1862650 @default.
• W3213679265 hasConceptScore W3213679265C188816634 @default.
• W3213679265 hasConceptScore W3213679265C22467394 @default.
• W3213679265 hasConceptScore W3213679265C2776301958 @default.
• W3213679265 hasConceptScore W3213679265C2779161974 @default.
• W3213679265 hasConceptScore W3213679265C2779951463 @default.
• W3213679265 hasConceptScore W3213679265C36289849 @default.
• W3213679265 hasConceptScore W3213679265C512399662 @default.
• W3213679265 hasConceptScore W3213679265C71924100 @default.
• W3213679265 hasIssue "Supplement 1" @default.
• W3213679265 hasLocation W32136792651 @default.
• W3213679265 hasOpenAccess W3213679265 @default.
• W3213679265 hasPrimaryLocation W32136792651 @default.
• W3213679265 hasRelatedWork W1988763878 @default.
• W3213679265 hasRelatedWork W2034542604 @default.
• W3213679265 hasRelatedWork W2056089772 @default.
• W3213679265 hasRelatedWork W2059250886 @default.
• W3213679265 hasRelatedWork W2083103840 @default.
• W3213679265 hasRelatedWork W2104570359 @default.
• W3213679265 hasRelatedWork W2218125013 @default.
• W3213679265 hasRelatedWork W2889182102 @default.
• W3213679265 hasRelatedWork W3010511938 @default.
• W3213679265 hasRelatedWork W4254819107 @default.
• W3213679265 hasVolume "138" @default.
• W3213679265 isParatext "false" @default.
• W3213679265 isRetracted "false" @default.
• W3213679265 magId "3213679265" @default.
• W3213679265 workType "article" @default.